Related references
Note: Only part of the references are listed.BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
Jamshid S. Khorashad et al.
BLOOD (2013)
Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications
Vera Grossmann et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
Brief report Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile
Wendy T. Parker et al.
BLOOD (2012)
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
Jorge Cortes et al.
BLOOD (2012)
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
Jan B. Egan et al.
BLOOD (2012)
Clonal competition with alternating dominance in multiple myeloma
Jonathan J. Keats et al.
BLOOD (2012)
Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing
S. -Y. Ko et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Application of next-generation sequencing technologies in virology
Alan D. Radford et al.
JOURNAL OF GENERAL VIROLOGY (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini et al.
BLOOD (2011)
Practical Advice for Determining the Role of BCR-ABL Mutations in Guiding Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia
Elias Jabbour et al.
CANCER (2011)
Mutational analysis in chronic myeloid leukemia: when and what to do?
Susan Branford et al.
CURRENT OPINION IN HEMATOLOGY (2011)
Sensitive Detection of BCR-ABL1 Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy
Wendy T. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation
Jonathan A. Schumacher et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
Detection of Minority Resistance during Early HIV-1 Infection: Natural Variation and Spurious Detection rather than Transmission and Evolution of Multiple Viral Variants
Sara Gianella et al.
JOURNAL OF VIROLOGY (2011)
The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories
A. Kohlmann et al.
LEUKEMIA (2011)
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
Franz X. Schaub et al.
BLOOD (2010)
SeaView Version 4: A Multiplatform Graphical User Interface for Sequence Alignment and Phylogenetic Tree Building
Manolo Gouy et al.
MOLECULAR BIOLOGY AND EVOLUTION (2010)
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history
E. Jabbour et al.
LEUKEMIA (2010)
APPLICATIONS OF NEXT-GENERATION SEQUENCING Sequencing technologies - the next generation
Michael L. Metzker
NATURE REVIEWS GENETICS (2010)
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Martin C. Mueller et al.
BLOOD (2009)
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
Simona Soverini et al.
BLOOD (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Timothy Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Sara Redaelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Understanding the Role of Mutations in Therapeutic Decision Making for Chronic Myeloid Leukemia
Elias Jabbour et al.
SEMINARS IN HEMATOLOGY (2009)
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
Thomas Ernst et al.
HAEMATOLOGICA (2008)
A new rapid and sensitive assay for detecting the T3151 BCR-ABL kinase domain mutation in chronic myeloid leukaemia
J. S. Khorashad et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
High-resolution melt curve analysis:: Initial screening for mutations in BCR-ABL kinase domain
Katerina Machova Polakova et al.
LEUKEMIA RESEARCH (2008)
Next-generation DNA sequencing
Jay Shendure et al.
NATURE BIOTECHNOLOGY (2008)
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2007)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P. Shah et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy:: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol
Marco Vignetti et al.
BLOOD (2007)
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
Simona Soverini et al.
HAEMATOLOGICA (2007)
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
D. W. Sherbenou et al.
LEUKEMIA (2007)
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
Miriam Puttini et al.
CANCER RESEARCH (2006)
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients; correlation with clonal cytogenetic evolution but not response to therapy
SG Willis et al.
BLOOD (2005)
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib
S Soverini et al.
CLINICAL CHEMISTRY (2004)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Share Paper
